Form 4: Fulcrum Therapeutics Director Rachel King Acquires 60,000 Stock Options

Director Rachel King of Fulcrum Therapeutics acquired 60,000 stock options on November 12, 2024, which vest monthly until November 2027.

Summary

• Rachel King, a director at Fulcrum Therapeutics, acquired 60,000 stock options on November 12, 2024.
• The options have an exercise price of $3.64.
• These options vest in equal monthly installments until November 12, 2027, contingent upon continued service.
• The options expire on November 11, 2034.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock option grants, which is neither positive nor negative in itself. It is a neutral event.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers when they acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry.
• Vesting schedules, such as the monthly vesting until November 2027, are typical for these types of grants.
• The exercise price of $3.64 is specific to Fulcrum Therapeutics and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• The stock option grant may have a minor positive impact on employee morale as it shows confidence in the company's future.
• Shareholders may view this as a positive sign of alignment between management and company performance.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, equity securities, Fulcrum Therapeutics, director, vesting